Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Bexion Pharmaceuticals (United States) | Researchclopedia

Back to institutions

Bexion Pharmaceuticals (United States)

Covington, Kentuckycompany

47

Works

83

Citations

4

h-index

Top Research Topics

Sphingolipid Metabolism and Signaling ATP Synthase and ATPases Research Cancer Treatment and Pharmacology

Top Researchers

Richard Curry Clinical Trial and Consulting

80 works2,041 citationsh-index: 12

Recent Research

BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.

Tariq Arshad,Michael Gazda,et al.

20260 citations

Nanoparticle-Based Drug Delivery

Cancer, Hypoxia, and Metabolism

Cell death mechanisms and regulation

Cancer, Lipids, and Metabolism

Caveolin-1 and cellular processes

Lipid Membrane Structure and Behavior

Nanoplatforms for cancer theranostics

Neuroblastoma Research and Treatments

Erythrocyte Function and Pathophysiology

Tim Stephens Queen Mary University of London

111 works1,795 citationsh-index: 22

Gilles Tapolsky Bexion Pharmaceuticals (United States)

43 works1,055 citationsh-index: 14

34 works574 citationsh-index: 12

Ray Takigiku Bexion Pharmaceuticals (United States)

24 works393 citationsh-index: 8

Tariq Arshad Bexion Pharmaceuticals (United States)

31 works313 citationsh-index: 4

A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.

Tariq Arshad,Michael Gazda,et al.

20260 citations

Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.

Tariq Arshad,Michael Gazda,et al.

20260 citations

Investigation of In-vitro Antioxidant and Cytotoxic Activity of Blumea lacera (Burm.f.) DC. Leaf Chloroform Extract

Mujtaba Ali Khan,Sanjoy Kumer Paul

20250 citations

DMG-12. Safety and Pharmacological Assessment of BXQ-350, a novel biologic Sphingolipid Metabolism Modulator, Combined with Radiotherapy, for Pediatric Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma

Tariq Arshad,Margot Lazow,et al.

20250 citations

A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma.

Tariq Arshad,Michael Gazda,et al.

20250 citations